Sumitomo Pharma reported FY2024 revenue of ¥398.8B, up ¥84.3B YoY, driven by robust U.S. sales of Orgovyx (+96.9%), Myfembree (+39%), and Gemtesa (+78.6%). FY2025 guidance sees revenue declining to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results